Lumida
/CLX
⌘K
Clorox Co

Clorox Co

CLX
$96.32USD-2.42%-2.39 today

MARKET CAP

11.6B

P/E (TTM)

14.3x

FWD P/E

14.5x

DAY RANGE

$96 – $100

52W RANGE

$85
$132

AI Summary

Stalk
Buy NowMedium

CLX has entered an early, fragile Stage 1 consolidation following a terminal decline, and mean-reversion eligibility combined with an active Lockout Rally pattern grants a medium-term bullish bias. Short-term timing is favorable now due to the Lockout Rally override and price holding above rising short-term EMAs, suggesting pullbacks into the 9/21 EMA support zone are optimal. However, the long-term trend remains bearish until a decisive breakout above the declining 200 DMA occurs.

  • Dividend yield 1.23% highlights reliable income amid volatility
  • ERP implementation complete, improving efficiency and decision-making
  • Q3 revenue down 5.2% YoY to $1.01 B, reflecting sales pressure
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

The Clorox Company (NYSE: CLX) operates in the consumer packaged goods sector, focusing on health and hygiene products as well as household cleaning solutions. The company maintains a diverse portfolio that includes brands such as Clorox bleach, Glad trash bags, and Purell hand sanitizer. Clorox is currently undergoing a digital transformation, leveraging investments in technology and innovation to enhance operational efficiency while facing macroeconomic challenges.

Bull says

  • Dividend yield 1.23% highlights reliable income amid volatility
  • ERP implementation complete, improving efficiency and decision-making
  • High brand equity with Clorox, Glad, Purell driving stable sales
  • Innovation pipeline (Clorox Pure) exceeds expectations with strong velocity
  • Essential products category shows resilience against macro pressures
  • Strong balance sheet quality enables investment in growth initiatives

Bear says

  • Q3 revenue down 5.2% YoY to $1.01 B, reflecting sales pressure
  • Gross margin declined 250–300 bps on higher oil and supply costs
  • Inflationary input costs to reduce Q4 margins by $20–25 M
  • Negative earnings yield points to fundamental earnings weakness
  • Competitive promotions erode share in trash bags and cat litter
  • Elevated leverage heightens capital strain amid margin compression

Investment themes with CLX

High Dividend Yield +0.32%

Companies paying above-average dividends

AVGO · JPM · XOM

Earnings Call · Q3 2026 · Mgmt. Guidance

Updated 05-01-2026neutral

Transcript signals

Bull points

  • So maybe let's start with growth. So we're adding, you know, a business of $800 million that has a solid track record of growing mid-single digits.
  • Our largest innovation with Clorox Pure, which is our allergen platform, has gone very well. We got early wins on distribution. We were online early. We're getting great reviews. Retailers are very excited, and they're excited for the next round that we have coming at the beginning of fiscal year 27.
  • the expansion of our Scentiva line, continue to do really well. We launched a new flavor in cherry blossom, and that has been our number one scent, and we're expanding that scent into different forms.

Bear points

  • 250 to 300
  • 200 basis points coming from the Gojo acquisition
  • 50 basis points of gross margin dilution
Read full transcript analysis ›